An evaluation of diabetes-related measures of control after 6 months of clinical pharmacy specialist intervention

Journal of Pharmacy Practice

Volumn 24, Issue 3, 2011, Pages 332-338

  Cripps, Rebecca J ^c   Gourley, Eric S ^a   Johnson, Wendy ^a   Cassidy, Regina ^a   Morgan, Timothy C ^a   Venugopal, Dharapuram ^a   McFarland, M Shawn ^a,b  

^a UNIVERSITY OF TENNESSEE   (United States)

^b UNIVERSITY OF TENNESSEE COLLEGE OF PHARMACY   (United States)

^c NONE

Author keywords

blood pressure; cholesterol; clinical pharmacist; diabetes; glycosylated hemoglobin; performance measures

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALPHA GLUCOSIDASE INHIBITOR; BIGUANIDE; HEMOGLOBIN A1C; INSULIN; LOW DENSITY LIPOPROTEIN; MEGLITINIDE; SULFONYLUREA; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; CLINICAL EVALUATION; CLINICAL PHARMACY; CLINICAL PHARMACY SPECIALIST INTERVENTION; CLINICAL PRACTICE; CROSS-SECTIONAL STUDY; DIABETES EDUCATION; DIABETES MELLITUS; DIABETIC PATIENT; DIASTOLIC BLOOD PRESSURE; DISEASE CONTROL; ELECTRONIC MEDICAL RECORD; FEMALE; FOLLOW UP; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LIFESTYLE MODIFICATION; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MEDICAL SOCIETY; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTPATIENT CARE; PATIENT CARE; PHARMACIST; PRACTICE GUIDELINE; RETROSPECTIVE STUDY; SMOKING CESSATION; SYSTOLIC BLOOD PRESSURE; TELECONSULTATION; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 79958102910     PISSN: 08971900     EISSN: 15311937     Source Type: Journal    
DOI: 10.1177/0897190010392235     Document Type: Article

References (49)

1. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007. http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2007.pdf. Accessed August 2, 2009.
2. Miller DR, Safford MM, Pogach LM. Who has diabetes? Best estimates of diabetes prevalence in the Department of Veterans Affairs based on computerized patient data. Diabetes Care. 2004 ; 27 (suppl 2). B10 - B21
3. Hogan P, Dall T, Nikolov P,. Economic costs of diabetes in the U.S. in 2002. Diabetes Care. 2003 ; 26 (3). 917-932
4. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control on health care costs and utilization. JAMA. 2001 ; 285 (2). 182-189 (Pubitemid 32048520)
5. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993 ; 329 (14). 977-86
6. Effect of intensive blood glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998 ; 352: 854-865
7. Intensive blood-glucose control with sulfonylureas or insulin compared to conventional treatment and risk comparison in patients with type 2 diabetes (UKPDS 33). Lancet. 1998 ; 352 (9131). 837-853
8. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 1995 ; 28 (2). 103-117
9. Association of glycemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): a prospective observational study. BMJ. 2000 ; 321: 405-412
10. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008 ; 358: 2545-2559
11. Hansson L, Zanchetti A, Carruthers S, et al. Effects of intensive blood- pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment (HOT) randomised trial: HOT study group. Lancet. 1998 ; 351 (9118). 1755-1762 (Pubitemid 28269185)
12. Curb J, Pressel S, Cutler J, et al. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension: systolic hypertension in the elderly program cooperative research group. JAMA. 1996 ; 276 (23). 1886-1892 (Pubitemid 26419185)
13. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000 ; 355 (9200). 253-259
14. Pyorala K, Pedersen T, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease: a subgroup analysis of the Scandinavian simvastatin survival study (4S). Diabetes Care. 1997 ; 20 (4). 614-620 (Pubitemid 27143424)
15. Goldberg R, Mellies M, Sacks F, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucose-intolerant myocardial infarction survivors with average cholesterol levels: subgroup analyses in the cholesterol and recurrent events (CARE) trial. Circulation. 1998 ; 98 (23). 2513-2519 (Pubitemid 29001188)
16. Rubins H, Robins S, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med. 1999 ; 341 (6). 410-418 (Pubitemid 29362514)
17. Standards of medical care in diabetes-2010. Diabetes Care. 2010 ; 33 (suppl 1). S11 - S61
18. Washington, DC: VA/DoD Clinical Practice Guideline Working Group, Veterans Health Administration, Department of Veterans Affairs and Health Affairs, Department of Defense, December 1999 ; Update 2003 :
19. Fleming BB, Greenfield S, Engelgau MM, et al. The Diabetes Quality Improvement Project: Moving science into health policy to gain an edge on the diabetes epidemic. Diabetes Care. 2001 ; 24 (10). 1815-1820 (Pubitemid 33716488)
20. Sawin CT, Walder DJ, Bross DS, et al. Diabetes process and outcome measures in the department of veterans affairs. Diabetes Care. 2004 ; 27 (suppl 2). B90 - B94
21. Department Hospital Report Card to the House Appropriations Committee of Veterans Affairs. Veterans Health Administration In response to House Appropriations Report No. 110-186, accompanying Public Law 110-161, The Consolidated Appropriations Act, 2008. http://hosted.ap.org/specials/ interactives/wdc/documents/va-care061308.pdf.Accessed August 20, 2008.
22. Maljanian R, Grey N, Staff I, et al. Improved diabetes control through a provider-based disease management program. Dis Manage Health Outcomes. 2002 ; 10: 1-8 (Pubitemid 34165409)
23. Deeb L, Pettijohn F, Shirah J, et al. Interventions among primary care practitioners to improve care for preventable complications of diabetes. Diabetes Care. 1988 ; 11 (3). 275-280
24. Norris S, Nichols P, Casperson C, et al. The effectiveness of disease and case management for people with diabetes: a systemic review. Am J Prev Med. 2002 ; 22 (suppl 4). 15-38 (Pubitemid 34436884)
25. Coast-Senior E, Kroner B, Kelley C, et al. Management of patients with type 2 diabetes by pharmacists in primary care clinics. Ann Pharmacother. 1998 ; 32 (6). 636-640
26. Choe HM, Mirtrovich S, Dubay D, et al. Proactive case management of high-risk patients with type 2 diabetes mellitus by a clinical pharmacist: a randomized controlled trial. Am J Manag Care. 2005 ; 11 (4). 253-260 (Pubitemid 40569748)
27. Odegard PS, Goo A, Hummel J, et al. Caring for poorly controlled diabetes mellitus: a randomized pharmacist intervention. Ann Pharmacother. 2005 ; 39: 433-440 (Pubitemid 40270910)
28. Cioffi ST, Caron MF, Kalus JS, et al. Glycosylated hemoglobin, cardiovascular, and renal outcomes in a pharmacist-managed clinic. Ann Pharmacother. 2004 ; 38 (5). 771-775 (Pubitemid 38509050)
29. Irons BK, Lenz RJ, Anderson SL, et al. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002 ; 22 (10). 1294-1300 (Pubitemid 35155082)
30. Anaya JP, Rivera JO, Lawson K, et al. Evaluation of pharmacist-managed diabetes mellitus under a collaborative drug therapy agreement. Am J Health-Syst Pharm. 2008 ; 65 (19). 1841-1845
31. CN Sadur, N Moline, M Costa, et al. Diabetes management in a health maintenance organization. Efficacy of care management using cluster visits. Diabetes Care. 1999 ; 22 (12). 2011-2017 (Pubitemid 30433981)
32. Hirsch IB, Goldberg HI, Ellsworth A, et al. A multifaceted intervention in support of diabetes treatment guidelines: a cont trial. Diabetes Res Clin Pract. 2002 ; 58: 27-36 (Pubitemid 34823622)
33. Rothman RL, Malone R, Bryant B, et al. A randomized trial of a primary care-based disease management program to improve cardiovascular risk factors and glycated hemoglobin levels in patients with diabetes. Am J Med. 2005 ; 118 (3). 276-284 (Pubitemid 40312639)
34. Nowak SN, Singh R, Clarke A, et al. Metabolic control and adherence to American Diabetes Association Practice Guidelines in a pharmacist-managed diabetes clinic. Diabetes Care. 2002 ; 25: 1479
35. Jacques CHM, Jones RL, Houts P, et al. Reported practice behaviors for medical care of patients with DM by primary care physicians in Pennsylvania. Diabetes Care. 1991 ; 14: 712-771
36. Survey of Physician Practice Behaviors Related to the Treatment of People With Diabetes Mellitus: Final Report. Washington, DC: National Institute of Diabetes and Digestive and Kidney Diseases ; 1990 :
37. Tuttleman M, Lipsett L, Harris MI. Attitudes and behaviors of primary care physicians regarding tight control of blood glucose in IDDM patients. Diabetes Care. 1993 ; 16 (5). 765-772 (Pubitemid 23127184)
38. Beckles GL, Engelgau MM, Narayan KM, et al. Population based assessment of the level of care among adults with diabetes in the US. Diabetes Care. 1998 ; 21: 1432-1438 (Pubitemid 28405192)
39. Ragucci KR, Fermo JD, Wessell AM, et al. Effectiveness of pharmacist-administered diabetes mellitus education and management services. Pharmacotherapy. 2005 ; 25 (12). 1809-1816 (Pubitemid 41790103)
40. Adler A, Stratton H, H Neil, et al. The Association of systolic with macrovascular and microvascular complications of diabetes (UKPDS-36): prospective observation study. BMJ. 2000 ; 321: 412-419 (Pubitemid 30609443)
41. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010 ; 362 (17). 1575-1585
42. MRC/BHF Heart'protection study of cholesterol lowering in 20 536 high risk individuals: a randomized placebo controlled trial. Lancet. 2002 ; 360: 7-22
43. Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collarborative Atorvastatin Diabetes Study (CARDS): multicentre randomized controlled trial. Lancet. 2004 ; 364 (9435). 685-696 (Pubitemid 39140624)
44. Marniemi J, Maki J, Maatela J, et al. Poor applicability of the Friedewald formula in the assessment of serum LDL cholesterol for clinical purposes. Clin Biochem. 1995 ; 28 (3). 285-289
45. Executive summary of the third report of the national cholesterol education program expert panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA. 2001 ; 110: 227-239
46. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomized controlled trial. Lancet. 2005 ; 366: 1849-1861
47. Kahn S, Haffner S, Heise M, et al. Glycemic durability of rosiglitazone, metformin or glyburide monotherapy. N Engl J'Med. 2006 ; 355: 2427-2443 (Pubitemid 44903747)
48. Wagner EH, Sandhu N, Newton KM, et al. Effect of improved glycemic control of health care costs and utilization. JAMA. 2001 ; 285 (2). 182-189 (Pubitemid 32048520)
49. Testa MA, Simonson DC. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. JAMA. 1998 ; 280 (17). 1490-1496 (Pubitemid 28507401)